Experimental intraocular penetration of dacarbazine.
Radioactive carbon (14C)-labeled dacarbazine was used to trace penetration of the drug to the eye after intravenous and subtenon-retrobulbar injection on experimental animals. After subtenonretrobulbar injection of 1 or 2.5 mg of commercial dacarbazine twice daily for two weeks, there were no clinical changes. However, doses of 5 to 7.5 mg per injection produced destructive chorioretinitis, and a proliferative type of retinopathy was confirmed histopathologically.
D000818:Animals; D002825:Chorioretinitis / Q000139:chemically induced; D002829:Choroid / Q000378:metabolism; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism* / Q000627:therapeutic use; D005123:Eye / Q000378:metabolism*; D000882:Haplorhini; D008253:Macaca mulatta; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D011817:Rabbits; D012160:Retina / Q000378:metabolism; D012164:Retinal Diseases / Q000139:chemically induced; D014226:Triazenes / Q000378:metabolism*
D014226:Triazenes; D003606:Dacarbazine